Top 10 Companies in the 1,2-Indandiol Market (2026): Market Leaders Powering Global Supply

MARKET INSIGHTS

Global 1,2-Indandiol market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.

1,2-Indandiol is a bicyclic organic compound belonging to the indane family, characterized by two hydroxyl groups at the 1 and 2 positions of the indane ring system. It exists as both cis and trans stereoisomeric forms, with each enantiomer holding considerable relevance in asymmetric synthesis and chiral chemistry. The compound serves as a valuable chiral building block in the synthesis of pharmaceuticals, agrochemicals, and fine chemicals, while also finding application in the development of biologically active molecules and as an intermediate in organic synthesis workflows.

The market is gaining steady momentum, driven primarily by growing demand for chiral intermediates in pharmaceutical manufacturing and the expanding scope of asymmetric catalysis research. Furthermore, increasing investments in fine chemical production and the rising focus on enantioselective synthesis methodologies are reinforcing market expansion. Key suppliers of high‑purity chiral compounds, including MilliporeSigma (Merck KGaA), TCI Chemicals, and Alfa Aesar (Thermo Fisher Scientific), maintain active portfolios featuring 1,2-Indandiol and its derivatives, supporting consistent supply across research and industrial end‑use segments.

1,2-Indandiol Market – View in Detailed Research Report

Top 10 Companies in the 1,2‑Indandiol Market (2026): Market Leaders Powering Global Supply

1. MilliporeSigma (Merck KGaA)

   Headquarters: Germany / USA
   Key Offering: Pharmaceutical‑grade 1,2‑Indandiol (both enantiopure and racemic), advanced chiral intermediates for API synthesis.

   MilliporeSigma has positioned itself as a benchmark in chiral chemistry, offering a portfolio that spans from research‑grade reagents to GMP‑compliant building blocks. Its robust quality management system and extensive analytical support make it the go‑to supplier for early‑stage research and large‑scale pharmaceutical production.

   Sustainability / Growth Initiatives: The company invests in green chemistry pathways, including enzyme‑catalyzed dihydroxylation and continuous flow processes, to reduce waste and energy consumption.

   • Biocatalytic process development for enantiomeric enrichment.
   • Partnerships with academic labs for new asymmetric transformations.
   • Commitment to carbon neutrality in manufacturing by 2030.

2. Thermo Fisher Scientific (Alfa Aesar)

   Headquarters: USA
   Key Offering: Research‑grade and pharmaceutical‑grade 1,2‑Indandiol, plus a wide range of chiral reagents.

   Alfa Aesar’s extensive distribution network ensures rapid delivery of high‑purity intermediates to laboratories worldwide. The company’s focus on scalable synthesis and rigorous purity testing supports both academic research and industrial API development.

   Sustainability / Growth Initiatives: Emphasis on solvent‑free processes and recyclable catalysts.

   • Implementation of aqueous phase biotransformations.
   • Development of modular synthesis platforms for rapid scale‑up.
   • Targeted reduction of hazardous waste streams.

3. TCI Chemicals

   Headquarters: Japan
   Key Offering: High‑purity 1,2‑Indandiol, specialty chiral intermediates, and custom synthesis services.

   TCI’s expertise in multi‑step organic synthesis and its global supply chain make it a preferred partner for complex API routes requiring precise stereochemistry.

   Sustainability / Growth Initiatives: Investment in renewable feedstocks and process intensification.

   • Use of bio‑derived indene precursors.
   • Adoption of continuous flow dihydroxylation.
   • Collaboration with contract manufacturers for green production.

4. Combi‑Blocks Inc.

   Headquarters: USA
   Key Offering: Modular chiral building blocks, including 1,2‑Indandiol derivatives for rapid synthesis.

   Combi‑Blocks specializes in providing pre‑functionalized chiral scaffolds that accelerate drug discovery pipelines, reducing synthetic cycles.

   Sustainability / Growth Initiatives: Focus on low‑waste, high‑yield transformations.

   • Development of enzyme‑mediated dihydroxylation kits.
   • Integration of automated synthesis modules.
   • Partnerships with pharma R&D labs for process optimization.

5. AK Scientific Inc.

   Headquarters: USA
   Key Offering: Specialty chiral reagents, including 1,2‑Indandiol for agrochemical and pharmaceutical applications.

   AK Scientific delivers high‑quality intermediates with a strong emphasis on analytical support and rapid turnaround.

   Sustainability / Growth Initiatives: Development of greener catalytic systems.

   • Use of recyclable metal catalysts.
   • Exploration of aqueous phase biocatalysis.
   • Continuous improvement of process safety.

6. Fluorochem Ltd.

   Headquarters: United Kingdom
   Key Offering: Fluorinated chiral intermediates and 1,2‑Indandiol derivatives for specialty applications.

   Fluorochem’s expertise in fluorination and chiral synthesis positions it as a niche supplier for high‑value specialty chemicals.

   Sustainability / Growth Initiatives: Adoption of green fluorination protocols.

   • Use of electrochemical fluorination.
   • Reduction of toxic fluorine waste.
   • Collaboration with green chemistry initiatives.

7. Jinan Dexinjia Biopharm Co., Ltd.

   Headquarters: China
   Key Offering: Large‑scale production of 1,2‑Indandiol for domestic and export markets.

   Jinan Dexinjia has expanded its synthetic portfolio to include indane derivatives, leveraging cost‑competitive manufacturing and improving quality capabilities.

   Sustainability / Growth Initiatives: Focus on process efficiency and waste minimization.

   • Implementation of closed‑loop solvent recovery.
   • Optimization of biocatalytic routes.
   • Compliance with international GMP standards.

8. Hangzhou Dayangchem Co., Ltd.

   Headquarters: China
   Key Offering: Custom synthesis of 1,2‑Indandiol and related intermediates.

   Hangzhou Dayangchem serves both domestic pharma and specialty chemical sectors with a flexible, rapid‑turnover manufacturing model.

   Sustainability / Growth Initiatives: Emphasis on renewable feedstocks and process intensification.

   • Use of bio‑derived indene.
   • Adoption of continuous flow synthesis.
   • Investment in green catalyst development.

9. BLD Pharm

   Headquarters: China
   Key Offering: Pharmaceutical‑grade 1,2‑Indandiol and chiral intermediates for API synthesis.

   BLD Pharm supplies high‑purity intermediates with rigorous quality control, catering to both domestic and international pharmaceutical manufacturers.

   Sustainability / Growth Initiatives: Focus on sustainable manufacturing practices.

   • Implementation of energy‑efficient reactors.
   • Reduction of hazardous waste.
   • Partnerships with green chemistry research groups.

10. Acros Organics (Thermo Fisher)

    Headquarters: Belgium / USA
    Key Offering: Research‑grade 1,2‑Indandiol and a wide range of chiral reagents.

    Acros Organics provides high‑quality reagents with comprehensive analytical data, supporting academic and industrial research.

    Sustainability / Growth Initiatives: Commitment to greener synthesis.

    • Development of recyclable catalysts.
    • Adoption of solvent‑free processes.
    • Collaboration with sustainability programs.

Download FREE Sample Report: 1,2‑Indandiol Market
Get Full Report

Outlook

The 1,2‑Indandiol market is poised to benefit from continued investment in antiviral and CNS drug development, alongside the expansion of fine‑chemical manufacturing in Asia‑Pacific. The convergence of green chemistry and biocatalysis is expected to lower production costs, making high‑purity enantiomers more accessible to mid‑sized pharmaceutical companies.

Future Trends

Key trends include the rise of biocatalytic dihydroxylation platforms, increased demand for enantiopure intermediates in generics and specialty pharmaceuticals, and a shift toward renewable feedstocks for indene synthesis. Regulatory focus on stereochemical purity will further drive the adoption of advanced chiral processes.